Indications for: VYVGART
Generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody positive.
Give by IV infusion over 60mins. 10mg/kg once weekly for 4 weeks. In patients weighing ≥120kg: 1200mg (3 vials) per infusion. Administer subsequent cycles based on clinical evaluation. Safety of initiating subsequent cycles sooner than 50 days from the start of the previous treatment cycle: not established.
Increased risk of infection; monitor. Delay treatment in those with an active infection until resolved. If serious infection occurs, treat appropriately and consider withholding Vyvgart until resolved. Evaluate for age-appropriate vaccinations according to guidelines prior to initiation of a new treatment cycle. Monitor for hypersensitivity reactions during and for 1hr thereafter; discontinue if occurs. Moderate or severe renal impairment. Pregnancy. Nursing mothers.
Neonatal Fc receptor blocker.
Concomitant live or live-attenuated vaccines: not recommended. May antagonize immunoglobulin products, monoclonal antibodies, or antibody derivatives containing the human Fc domain of the IgG subclass; closely monitor for reduced effects; if concomitant long-term use is necessary, consider discontinuing Vyvgart and use alternatives.
Respiratory tract infection, headache, urinary tract infection, paresthesia, myalgia.
Generic Drug Availability:
Single-dose vial (20mL)—1